Document:

Exhibit
4.12

 

Execution Copy

 

SHARE
PURCHASE AGREEMENT

 

This
SHARE PURCHASE AGREEMENT is made as of this 7th day of August, 2018 (this “Agreement”), by and between
ELBIT IMAGING LTD., a public company incorporated under the laws of the State of Israel (Company No. 52-004303-5) (the
“Seller”) and FOCUSED HOLDINGS 3, as a Series of ECG LP, a limited partnership organized and existing
under the laws of Delaware (the “Purchaser”, and together with the Seller, each is referred to as a “Party”
and collectively as the “Parties”).

 

WHEREAS,
the Seller is the legal and beneficial holder of ordinary shares, no par value (“Ordinary Shares”) of Elbit
Medical Technologies Ltd., a public company incorporated under the laws of the State of Israel (Company No. 52-003964-5) (the
“Company”); and

 

WHEREAS,
the Seller desires to sell to the Purchaser, and the Purchaser desires to purchase from the Seller, up to an aggregate of 115,741,467
Ordinary Shares held legally and beneficially by the Seller (the “Maximum Amount”), at a price per Ordinary
Share of NIS 0.96 (the “Price Per Share”) and an aggregate investment amount of up to NIS 111,111,808.32 (the
“Purchase Price”), all pursuant to the terms and conditions more fully set forth in this Agreement.

 

NOW,
THEREFORE, in consideration of the mutual promises and covenants set forth herein, the Parties hereby agree as follows:

 

1.
Purchase and Sale of the Sale Shares.

 

1.1.
Sale of Shares. Subject to the terms and conditions hereof, at the Initial and the Deferred Closings (as defined in Section
‎1.3 below), the Seller shall sell to the Purchaser, and the Purchaser shall purchase from the Seller, up to 115,741,467
Ordinary Shares, at the Price Per Share, each having the rights and preferences and privileges set forth in the Company’s
Articles of Association (the “Articles”), which constitute on the date hereof 50% of the issued and outstanding
share capital of the Company, and 32.6% of the issued and outstanding share capital of the Company on a Fully Diluted Basis (as
defined herein). Any Ordinary Shares purchased hereunder will be transferred by the Seller to the Purchaser upon the payment by
the Purchaser to the Seller of the relevant portion of the Purchase Price by means of an “off-the-market” block sale
transaction executed by the TASE members representing each of the parties, or other method agreed to by the Parties.

 

For
purposes hereof, “Fully Diluted Basis” means taking into account all issued shares, warrants, options, convertible
loans, rights and convertible securities, on an as-if exercised and as-converted basis (including all rights and promises of any
kind that could directly or indirectly result in the acquisition of Ordinary Shares from the Company).

 

1.2.
Initial Closing. The initial closing of the sale and purchase of an aggregate number of 11,574,146 Ordinary Shares (the
“Initial Sale Shares”) shall take place on August 27, 2018, or at such other time and place as mutually agreed
to by the Parties (the “Initial Closing”). The Initial Closing shall be deferred by up to seven (7) days upon
the Purchaser’s prior written request.

 

1.3.
Deferred Closings. Subject to the consummation of the Initial Closing, during the period beginning upon completion of the
Initial Closing and ending at 17:00 Israel time on November 26, 2018 (the “Deferred Closings Period”), the
Purchaser shall have the right, but not the obligation, upon delivery to the Seller of at least five (5) business days’
prior written notice, to purchase additional Ordinary Shares at the Price Per Share (the “Deferred Sale Shares”,
and together with the Initial Sale Shares, the “Sale Shares”) in one or more deferred closings (each a “Deferred
Closing” and, collectively, the “Deferred Closings”, and together with the Initial Closing, each
shall be referred to as a “Closing”), up to an aggregate amount of Deferred Sale Shares at any Deferred Closing
equal to: (i) the Maximum Amount; minus (ii) the Initial Sale Shares; minus (iii) any Deferred Sale Shares already
purchased by the Purchaser; minus (iv) any Ordinary Shares sold by the Seller to a thirty party with respect to which it
paid the Purchaser the Compensation (as defined in Section ‎4.3(b) below) (the “Adjusted Maximum Amount”);
provided that the consideration for the Deferred Sale Shares purchased in any such Deferred Closing (other than the final Deferred
Closing) must be equal to or greater than NIS 10,000,000.

 

     

     

    

 

1.4.
Conditions Precedent.

 

(a)
The obligations of the Purchaser at a Closing are subject to the satisfaction of each of the following conditions on or prior
to such Closing, any of which may be waived by the Purchaser in its sole discretion:

 

(i)
The representations and warranties of the Seller shall be true and correct in all material respects as of the date hereof and
as of such Closing as though made at that time, and the Seller shall have performed, satisfied and complied in all material respects
with the covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by it at
or prior to such Closing.

 

(ii)   
To the extent required under law, any regulatory approval for the sale and purchase of the Sale Shares shall have been obtained.

 

(iii)
The Seller shall have delivered to the Purchaser the voting agreement in the form attached hereto as Exhibit A
(the “Voting Agreement”), dated as of the Initial Closing, duly executed by the Seller.

 

(b)
The obligations of the Seller at a Closing are subject to the satisfaction of each of the following conditions on or prior to
such Closing, any of which may be waived by the Seller in its sole discretion:

 

(i)
The representations and warranties of the Purchaser shall be true and correct in all material respects as of the date hereof and
as of such Closing as though made at that time.

 

(ii)
To the extent required under law, any regulatory approval for the sale and purchase of the Sale Shares shall have been obtained.

 

(iii)
The Purchaser shall have delivered to the Seller the Voting Agreement, dated as of the Initial Closing, duly executed by the Purchaser.

 

2.
Adjustments.

 

2.1.
Adjustments. Notwithstanding anything to the contrary herein, the Price Per Share hereunder and the number and kind of
Sale Shares issuable hereunder are subject to adjustment, in the event of changes in the outstanding Ordinary Shares of the Company
by reason of any distributions (of shares, securities or other property of the Company, by way of dividend or otherwise), share
splits, reverse-share splits, or reclassifications, or any other similar event, the number and class of shares available for purchase
by the Purchaser under this Agreement in the aggregate, and the Price Per Share, shall be correspondingly adjusted to give the
Purchaser the total number, class and kind of shares as the Purchaser would have owned had this Agreement been exercised immediately
prior to the event and had the Purchaser continued to hold such shares until immediately after the event requiring adjustment.

 

2.2.
Certificate as to Adjustment. Whenever there is an adjustment pursuant to Section ‎2.1, the Seller shall promptly
issue and deliver to the Purchaser a certificate setting forth, in reasonable detail, the nature of the adjustment, the adjusted
Price Per Share, and the number, class and kind of Sale Shares purchasable hereunder after giving effect to such adjustment. The
form of this Agreement need not be changed because of any adjustment in the number, class or kind of shares in the Company subject
to this Agreement or any adjustment in the Price per Share.

 

    2

     

    

 

3.
Representations and Warranties.

 

3.1.
Each Party represents and warrants to the other Party, as of the date of the Closing, as follows:

 

(a)
Authorization; Validity. It has full power and authority to execute and deliver this Agreement and to perform its obligations
hereunder. This Agreement has been duly executed and delivered and constitutes the lawful, valid and legally binding obligation
of such Party, enforceable in accordance with its applicable terms and conditions.

 

(b)
No Breach. Neither the execution and delivery of this Agreement, or any ancillary document attached hereto, nor compliance
by such Party with the terms and provisions hereof or thereof, will conflict with, or result in a breach or violation of, any
of the terms, conditions and provisions of: (i) any judgment, order, injunction, decree, or ruling of any court or governmental
authority, domestic or foreign to which such Party is party or by which such Party is bound; (ii) any agreement, contract, lease,
license or commitment to which such Party is a party or to which it is subject, or to which any of its properties is subject;
or (iii) applicable law, statute, ordinance, or regulation.

 

3.2.
The Purchaser represents and warrants to the Seller as follows:

 

(a)
Investment Purpose; No Affiliation with Other Investors; No Controlling Interest. The Purchaser is purchasing the Sale
Shares for its own account and not in conjunction with any other party purchasing the Sale Shares under the terms and conditions
hereof. The Purchaser is purchasing for investment purposes only and not with a view to, or for resale in connection with, the
public sale or distribution thereof. There are no agreements between the Purchaser and any other party with respect to the purchase
or sale of securities of the Company or with respect to the voting rights in the Company other than pursuant to the Voting Agreement.

 

(b)
Knowledge and Experience. The Purchaser has such knowledge and experience in financial and business matters as to be capable
of evaluating the merits and risks of its investment in the Company, has evaluated the merits and risks of such investment, accepts
the terms and conditions of such investment, has the ability to bear the economic risks of its investment for an indefinite period
of time, can afford the complete loss of its investment and recognizes that an investment in the Company involves substantial
risk.

 

(c)
Access to Information. The Purchaser acknowledges that the Company files reports regarding material aspects of its activity
in accordance with the Israeli Securities Law, 5728-1968 (the “Securities Law”) and the regulations promulgated
thereunder, and that such reports are available to the Purchaser.

 

(d)
General Solicitation. The Purchaser is not purchasing the Sale Shares as a result of, and the Purchaser is not aware of,
any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar relating to the sale of the Sale Shares.

 

(e)
No Other Representations and Warranties. Except for the representations and warranties expressly and specifically made
by the Seller in this Agreement, the Seller does not make any express or implied representation or warranty, and the Seller hereby
disclaims all other representations and warranties of any kind or nature, express or implied.

 

    3

     

    

 

(f) 
The Securities Law and the Israeli Companies Law. The Purchaser acknowledges that the Company is a public company and the
Ordinary Shares are listed for trade on the Tel Aviv Stock Exchange. The Company is subject to the Securities Law and the Israeli
Companies Law, 5759-1999 including (but not limited to) provisions in respect of: (i) shareholders’ responsibilities (including
the obligation of a major shareholder to update the Company on any transaction in its shares; (ii) prohibition of the use of inside
information about the Company; and (iii) prohibition of acquiring (including together with others) 90% or more of the Company’s
outstanding share capital, except by means of a full tender offer.

 

3.3.
The Seller represents and warrants to the Purchaser as follows:

 

(a)
Sale Shares.

 

(i)
All Sale Shares have been duly and validly issued, and are fully paid and non-assessable.

 

(ii)
The Seller is the lawful owner, beneficially and of record, of all of the Sale Shares being transferred by the Seller hereunder
and of all rights thereto, which Sale Shares are, and shall be upon transfer hereunder, free and clear of all liens, claims, charges,
encumbrances, restrictions, rights, options to purchase, proxies, voting trust and other voting agreements, calls or commitments
of any kind, other than any such rights and restrictions that are applicable to the Sale Shares pursuant to the Articles.

 

(iii)
The Maximum Amount constitutes 50% of the issued and outstanding share capital of the Company, and 32.6% of the issued and outstanding
share capital of the Company on a Fully Diluted Basis on the date hereof.

 

(b)
Disputes. There is no suit, action, proceeding, claim or investigation pending or, to the knowledge of the Seller, threatened,
against the Seller that seeks to prevent the Seller from consummating the transactions contemplated by this Agreement.

 

(c)
Accuracy of Public Disclosures. All of the information included in the Company’s public reports and filings (filed
with the Israel Securities Authority or with the Tel Aviv Stock Exchange) made since January 1, 2016 were accurate in all material
respects as of the date of publication. Since January 1, 2016, any material information which was required to be disclosed to
the public under Israeli law, has been disclosed by the Company in accordance with applicable law.

 

3.4.
The representations and warranties of each Party contained in this Section ‎3 shall survive the Closing hereunder and
continue in full force and effect thereafter.

 

4.
Fiduciary Duty; Right of First Refusal; Compensation; Co-Sale.

 

4.1.
Sale of Ordinary Shares to Third Parties.

 

(a)
During the Deferred Closings Period the Seller shall not sell any Ordinary Shares out of the Maximum Amount (as adjusted according
to Section 1.3 above) except in accordance with the provisions of this Section ‎4, and, in no event, for a price of
less than 107.5% of the Price Per Share.

 

(b)
The Seller shall comply with the provisions of this Section ‎4 until the earlier of: (a) the end of the Deferred Closings
Period; and (b) the time at which the Adjusted Maximum Amount has been reduced to zero.

 

4.2.
Right of First Refusal.

 

(a)
If at any time during the Deferred Closings Period, the Seller receives a bona fide binding offer from a third party (a
“Proposed Purchaser”) to acquire any number of Ordinary Shares (the “Proposed Shares”) for
a price per share that is at least 107.5% of the Price Per Share (the “Proposed PPS” and the “Offer”,
respectively), and the Seller wishes to sell, assign, transfer, or otherwise dispose of (each, a “Transfer”)
the Proposed Shares on such terms, then the Purchaser shall have a right of first refusal to acquire up to an aggregate amount
of Ordinary Shares equal to the Adjusted Maximum Amount for the Proposed PPS, in accordance with the provisions set forth in this
Section ‎4 (the “ROFR Shares”).

 

    4

     

    

 

(b)
The Seller shall provide the Purchaser with an offer stating the terms of the proposed Transfer (the “ROFR Notice”).
The Purchaser may accept the terms of purchase set forth in the ROFR Notice by giving the Seller notice to that effect (the “ROFR
Acceptance”) within ten (10) business days after being served with the ROFR Notice (the “Acceptance Period”).

 

(c)
The ROFR Acceptance shall include the date on which the Purchaser will purchase the ROFR Shares in consideration for the Proposed
PPS, which shall be on or by the later of: (i) five (5) business days after the date of the ROFR Acceptance; and (ii) three (3)
days prior to the proposed date of closing of the Transfer of the Proposed Shares in the Offer.

 

4.3.
Termination Notice.

 

(a)
If the Purchaser either: (i) does not deliver a ROFR Acceptance to the Seller during the Acceptance Period or (ii) delivers a
ROFR Acceptance to the Seller during the Acceptance Period, but fails to comply with its obligations with respect to acquiring
the ROFR Shares within the above mentioned time frame, then the Seller shall be entitled to accept the Offer (at a price per share
equal to or higher than the Proposed PPS), and if the Seller does accept the Offer, then it shall notify the Purchaser of such
acceptance of the Offer and the automatic termination of this Agreement with respect to such number of Ordinary Shares actually
sold to the Proposed Purchaser (a “Termination Notice” and the “Sold Shares” respectively),
the details of which shall include the identity of the Proposed Purchaser, the Proposed PPS, and any other terms and conditions
of the acquisition.

 

(b)
In consideration for the Purchaser’s time and effort and expenses in connection with this Agreement with respect to the
number of Sold Shares subject to that Termination Notice, the Seller shall pay to the Purchaser, on or by the date of the consummation
of the sale of the Sold Shares, a fee (the “Compensation”) equal to:

 

(i)
for the first NIS 10,000,000 of the Increased Consideration (calculated in accordance with Section ‎4.3(c) below),
a fee equal to 15% of the Increased Consideration; and

 

(ii)
thereafter, a fee equal to 5% of the Increased Consideration in excess of the first NIS 10,000,000 of the Increased Consideration.

 

(c)
For the purpose of Section ‎4.3(b), “Increased Consideration” is calculated using the following
formula:

 

	IC	=	SS x (CPPS – PPS)
	Where:	 
	IC	=	the Increased Consideration.
	SS	=	the Sold Shares.
	CPPS	=	the higher of (A) the Proposed PPS and (B) 110% of the Price Per Share.
	PPS	=	the Price Per Share.

 

4.4.
Co-Sale Right. Within five (5) business days of being served with the Termination Notice (the “Election Period”),
the Purchaser may deliver to the Seller a notice in which it elects to participate in the sale of the Sold Shares to the Proposed
Purchaser (the “Co-Sale Election”). In the event that the Purchaser delivers the Co-Sale Election, then the
Purchaser shall sell to the Proposed Purchaser, at the Proposed PPS, the Ordinary Shares it has already acquired under this Agreement
on the same terms and conditions as set forth in the Offer, such that the Purchaser shall Transfer to the Proposed Purchaser the
number of Ordinary Shares equal to: (a) the Proposed Shares; multiplied by (b) (i) the aggregate number of Ordinary Shares
held by it; divided by (ii) the aggregate number of Ordinary Shares held by the Parties; and the number of Ordinary Shares
to be sold by the Seller pursuant to the Offer shall be reduced accordingly.

 

    5

     

    

 

5.
Miscellaneous.

 

5.1.
Notices.

 

(a)
Any notice required or permitted to be given by either Party under this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of: (i) personal delivery; (ii) transmission, if transmitted by electronic mail during normal business
hours of the recipient, or, if not sent during normal business hours, the recipient’s next business day (provided, that,
in either case, the transmitting party shall not have received a bounce-back or other notice of the failure of such delivery);
(iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv)
two (2) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day
delivery, with written verification of receipt.

 

(b)
Until receipt of written notice to the contrary, the Parties’ addresses for notices are as follows:

 

	Seller	 	Purchaser
	Elbit
    Imaging Ltd.	 	Focused
    Holdings 3, as a series of ECG LP
	3
    Shimshon St., Olympia C Tower	 	250
    Park Avenue , 7th Floor
	Petach
    Tikva, 4900102 Israel	 	New
    York, NY 10177
	Attn:
    Yael Naftali, CFO	 	Attn:
    Sim Mann
	Email:
    Yaele@elbitimaging.com	 	Email:
    smann@exigentcap.com

 

5.2.
Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the
respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement. None of the rights, privileges, or obligations
set forth in, arising under, or created by this Agreement may be assigned or transferred without the prior consent in writing
of the Seller and the Purchaser.

 

5.3.
Governing Law; Jurisdiction. This Agreement shall be governed by and construed according to the laws of the State of Israel,
without regard to the conflict of laws provisions thereof. Any dispute arising under or in relation to this Agreement shall be
resolved exclusively in the competent courts of Tel Aviv, Israel, and each Party hereby irrevocably submits to the exclusive jurisdiction
of such courts.

 

5.4.
Counterparts. This Agreement may be executed and delivered by PDF format or other electronic transmission and in two or
more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

    6

     

    

 

5.5.
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.

 

5.6.
Amendments and Waivers. Any term of this Agreement may be amended, terminated or waived (either prospectively or retroactively
and either generally or in a particular instance) only with the written consent of the Seller and the Purchaser.

 

5.7.
Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability
of any other provision.

 

5.8.
Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching
or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or
of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a
waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind
or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of
any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set
forth in such writing.

 

5.9.
Entire Agreement. This Agreement (including the Schedules hereto) constitutes the full and entire understanding and agreement
between the Parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject
matter hereof existing between the parties are expressly canceled.

 

5.10.
Expenses. Each Party shall pay all of its own costs and expenses it incurs with respect to the negotiation, execution,
delivery and performance of this Agreement.

 

[Remainder
of Page Intentionally Left Blank]

 

    7

     

    

 

IN
WITNESS WHEREOF, the parties have executed this Share Purchase Agreement as of the date first written above.

 

	SELLER	 	PURCHASER
	 	 	 
	ELBIT
    IMAGING LTD.	 	FOCUSED
    HOLDINGS 3, as a Series of ECG LP
	 	 	 
	By:	      	 	By:	              
	Name:	 	 	Name:	 
	Title	 	 	Title	 

 

EXHIBIT
A: Voting Agreement

 

     

     

    

 

EXHIBIT
A: VOTING AGREEMENT

 

This
VOTING AGREEMENT (this “Agreement”) is made as of this __ day of July, 2018 (the “Effective
Date”), by and between ELBIT IMAGING LTD., a public company incorporated under the laws of the State of Israel
(Company No. 52-004303-5) (the “Elbit Imaging”) and FOCUSED HOLDINGS 3, as a Series of ECG LP, a limited
partnership organized and existing under the laws of Delaware (“Exigent”, and together with Elbit Imaging,
each is referred to as a “Party” and collectively as the “Parties”).

 

WHEREAS,
the Parties are the legal and beneficial holders of ordinary shares, no par value (“Ordinary Shares”) of Elbit
Medical Technologies Ltd., a public company incorporated under the laws of the State of Israel (Company No. 52-003964-5) (the
“Company”); and

 

WHEREAS,
the Parties desire to set forth certain matters regarding their holdings in the Company and to provide for the continuing representation
of the Parties on the Board of Directors of the Company in the manner set forth below.

 

NOW,
THEREFORE, in consideration of the mutual promises and covenants set forth herein, the Parties hereby agree as follows:

 

6.
Composition of the Board of Directors.

 

6.1.
Each Party undertakes to vote or cause to be voted all Ordinary Shares owned by it (including without limitation, any Ordinary
Shares owned by it upon exercise or conversion of any options, warrants or other convertible securities it holds) (the “Voting
Securities”) at any General Meeting of the Company (a “General Meeting”) at which members of the
Company’s Board of Directors (the “Board”) are appointed, on the terms set forth herein.

 

6.2.
The parties agree that if Exigent is the legal and beneficial holder of ten percent (10%) or more of the Company’s issued
and outstanding Ordinary Shares then the Board shall be comprised of seven (7) members, of whom:

 

(a)
two (2) members of the Board shall be external directors (“dahatzim”), in accordance with Section 239 of the
Israeli Companies Law 5759-1999 (the “External Directors”);

 

(b)
one (1) member of the Board shall be an independent director as defined under the Nasdaq rules and regulations (the “Independent
Director”); and

 

(c)
four (4) members of the Board shall be appointed in accordance with Section ‎1.3.

 

6.3.
The Parties shall use their Voting Securities to elect the members of the Board (excluding the Independent Director) (the “Board
Members”) as follows:

 

(a)
If Exigent is the legal and beneficial holder of less than ten percent (10%) of the Company’s issued and outstanding Ordinary
Shares, then all candidates to serve as Board Members will be nominated by Elbit Imaging; and the Parties will vote in favor of
electing those candidates.

 

    Ex.A-1

     

    

 

(b)
If Exigent is the legal and beneficial holder of ten percent (10%) or more of the Company’s issued and outstanding Ordinary
Shares but less than thirty percent (30%) of the Company’s issued and outstanding Ordinary Shares, then (i) five (5) candidates
to serve as Board Members (including the two (2) candidates to serve as External Directors) will be nominated by Elbit Imaging
and (ii) one (1) candidate will be nominated by Exigent; and the Parties will vote in favor of electing those candidates;

 

(c)
If Exigent is the legal and beneficial holder of thirty percent (30%) or more of the Company’s issued and outstanding Ordinary
Shares but less than forty percent (40%) of the Company’s issued and outstanding Ordinary Shares, then (i) four (4) candidates
to serve as Board Members (including one (1) candidate to serve as an External Director) will be nominated by Elbit Imaging; and
(ii) two (2) candidates to serve as Board Members (including one (1) candidate to serve as an External Director) will be nominated
by Exigent; and the Parties will vote in favor of electing those candidates; and

 

(d)
If Exigent is the legal and beneficial holder of forty percent (40%) or more of the Company’s issued and outstanding Ordinary
Shares, then: (i) three (3) candidates to serve as Board Members (including one (1) candidate to serve as an External Director)
will be nominated by Elbit Imaging, and (ii) three (3) candidates to serve as Board Members (including one (1) candidate to serve
as an External Director) will be nominated by Exigent; and the Parties will vote in favor of electing those candidates.

 

6.4.
The Party holding the majority of Ordinary Shares held by the Parties (the “Majority Party”) shall, after consultation
with the other Party, nominate the candidates for the positions of Independent Director, and the Parties shall vote their Voting
Securities to vote in favor of electing the Independent Director nominated by the Majority Party. For the avoidance of doubt,
the Majority Party shall have no obligation to accept any recommendation of candidates for the positions of Independent Director
from the other Party.

 

6.5.
Notwithstanding the foregoing, in the event of the termination or vacancy of position of a member of the Board, who was nominated
by a Party (in this section, the “Nominating Party”), then, subject to a notice by the Nominating Party of
its wish to fill such vacancy, each Party shall use its best efforts, subject to applicable law, to cause the Company to call
for a General Meeting for the election of a replacement member whose identity will be determined by the Nominating Party and to
vote or cause to be voted all of its Voting Securities in favor of the election of such candidate.

 

6.6.
A Nominating Party is not obligated to exercise its rights to nominate a member of the Board as stipulated in this section and
the exercise of such rights is subject to the Nominating Party’s full discretion. The fact that a Nominating Party has not
exercised its rights immediately following the creation of a vacancy in the Board or for any period of time afterwards, shall
not be deemed to be, or construed as, a waiver by such Nominating Party of its rights under this Agreement, and the other Party
shall act to fulfill its obligations under this Agreement immediately after the Nominating Party has notified of its wish to exercise
its rights under the Agreement.

 

6.7.
The Parties shall not vote to terminate the office of a member of the Board who was nominated by a Party without obtaining the
prior written consent of the nominating Party.

 

6.8.
Each Party undertakes not to vote any Voting Securities (whether at a meeting of shareholders or by written consent in lieu of
a meeting of shareholders) with respect to the election, removal or replacement of the members of the Board or their replacements
unless in accordance with the provisions of this Agreement.

 

6.9.
In the event of any share split, share dividend, recapitalization, reorganization, combination or the acquisition or receipt of
additional Company shares, the provisions of this Agreement shall apply also to any Ordinary Shares issued to or otherwise held
by the Parties.

 

7.
Right of First Offer.

 

7.1.
Subject to Section ‎2.2 below, in the event that a Party (the “Transferor”) wishes to sell, assign,
transfer, or otherwise dispose of (other than by way of the pledge, hypothecation or grant of any security interest in (each,
a “Lien”) any Ordinary Shares held by a Party, to the extent that such Lien expressly provides by its terms
that the realization of such Lien and the resulting intended transfer of the shares underlying such Lien shall be considered a
Transfer for all intents and purposes of, and be subject to all of the provisions governing Transfers of shares under these Agreement,
including for purposes of this Section ‎2) (each, a “Transfer”) its Ordinary Shares, then it shall
only do so in accordance with the following provisions (the “ROFO”):

 

    Ex.A-2

     

    

 

(a)
The Transferor deliver a notice (a “ROFO Notice”) to the other Party (the “Entitled Shareholder”)
stating: (i) its bona fide intention to Transfer Ordinary Shares held by it; (ii) the number of such Ordinary Shares to be offered
(the “Offered Shares”); and (iii) the price and terms, if any, upon which it proposes to Transfer such Offered
Shares.

 

(b)
The Entitled Shareholder shall have fifteen (15) days after receiving the ROFO Notice (the “Acceptance Period”)
to deliver to the Transferor an offer (a “ROFO Offer”) to acquire all or any portion of the Offered Shares,
in which it shall state: (i) the amount of Ordinary Shares it will purchase out of the Offered Shares (the “Purchased
Shares”); (ii) the price per share for which it will pay for the Purchased Shares (the “ROFO PPS”);
and (iii) the date on which the Entitled Shareholder will purchase the Purchased Shares in consideration for the ROFR PPS, which
shall be no more than five (5) business days after the end of the Acceptance Period (the “Payment Date”). A
failure by the Entitled Shareholder to deliver a ROFO Offer during the Acceptance Period or to pay the full consideration for
the Purchased Shares (calculated by multiplying the: (a) number of Purchased Shares; by (b) the ROFO PPS) on the Payment Date,
shall be deemed to be a waiver of its ROFO with respect to the proposed Transfer of such Offered Shares.

 

(c)
If the Entitled Shareholder either waives its ROFO, does not deliver a ROFO Offer during the Acceptance Period, or does not pay
the full consideration for the Purchased Shares on the Payment Date, then the Transferor may, during the period of ninety (90)
days following the expiration of the Acceptance Period (“Permitted Sale Period”), offer the Offered Shares
to any person or persons at a price higher than the ROFO PPS. If the Transferor does not consummate an agreement during the Permitted
Sale Period, then the Transfer of the Offered Shares shall again be subject to the provisions of this Section ‎2.1.

 

7.2.
Notwithstanding the foregoing, the ROFO in Section ‎2.1 above shall not apply to any Transfer by a Transferor of up to three
and a half percent (3.5%) of the issued and outstanding share capital of the Company in any forty-five (45) day period.

 

8.
Termination.

 

Either
party may terminate this Agreement following the third (3rd) anniversary of the Effective Date. This Agreement shall
automatically terminate at the time at which either Party no longer holds any Ordinary Shares.

 

9.
No Revocation.

 

The
Voting Agreement is coupled with an interest and may not be modified, amended, revoked or terminated, except by expiration or
termination in accordance with Section ‎3 above or an amendment effected in accordance with Section ‎5.6 hereof.

 

    Ex.A-3

     

    

 

10.
Miscellaneous.

 

10.1.
Notices.

 

(a)
Any notice required or permitted to be given by either Party under this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of: (i) the day of personal delivery; (ii) transmission, if transmitted by electronic mail during normal
business hours of the recipient, or, if not sent during normal business hours, the recipient’s next business day (provided,
that, in either case, the transmitting party shall not have received a bounce-back or other notice of the failure of such delivery);
(iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv)
two (2) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day
delivery, with written verification of receipt.

 

(b)
The Parties’ addresses for notices are as follows:

 

	Elbit
    Imaging	 	Exigent
	 	 	 
	Elbit
    Imaging Ltd.	 	Focused
    Holdings 3, as a series of ECG LP
	3
    Shimshon St., Olympia C Tower	 	250
    Park Avenue , 7th Floor
	Petach
    Tikva, 4900102 Israel	 	New
    York, NY 10177
	Attn:
    Yael Naftali, CFO	 	Attn:
    Sim Mann
	Email:
    Yaele@elbitimaging.com	 	Email:
    smann@exigentcap.com

 

10.2.
Successors and Assigns. Nothing in this Agreement, express or implied, is intended to confer upon any party other than
the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason
of this Agreement, except as expressly provided in this Agreement. None of the rights, privileges, or obligations set forth in,
arising under, or created by this Agreement may be assigned or transferred without the prior written consent of the Parties.

 

10.3.
Governing Law; Jurisdiction. This Agreement shall be governed by and construed according to the laws of the State of Israel,
without regard to the conflict of laws provisions thereof. Any dispute arising under or in relation to this Agreement shall be
resolved exclusively in the competent courts of Tel Aviv, Israel, and each Party hereby irrevocably submits to the exclusive jurisdiction
of such courts.

 

10.4.
Counterparts. This Agreement may be executed and delivered by PDF format or other electronic transmission and in two or
more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

10.5.
Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.

 

10.6.
Amendments and Waivers. Any term of this Agreement may be amended, terminated or waived (either prospectively or retroactively
and either generally or in a particular instance) only with the written consent of Elbit Imaging and Exigent.

 

10.7.
Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability
of any other provision.

 

    Ex.A-4

     

    

 

10.8.
Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching
or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or
of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a
waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind
or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of
any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set
forth in such writing.

 

10.9.
Entire Agreement. This Agreement constitutes the full and entire understanding and agreement between the Parties with respect
to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the
parties are expressly canceled.

 

10.10.
Expenses. Each Party shall pay all of its own costs and expenses it incurs with respect to the negotiation, execution,
delivery and performance of this Agreement.

 

IN WITNESS WHEREOF, the parties have executed this Voting Agreement as of the
date first written above.

 

	ELBIT
    IMAGING LTD.	 	FOCUSED
    HOLDINGS 3, as a Series of ECG LP
	 	 	 
	By:	      	 	By:	           
	Name:	 	 	Name:	 
	Title	 	 	Title	 

 

 

Ex.A-5Exhibit 4.13

 

Execution
Copy

 

Trust
agreement

 

This
Escrow Agreement (the “Agreement”) dated as of December 5, 2018 (the “Effective Date”), is entered
into by and among Elbit Ultrasound BV (a Company incorporated under the laws of the state of Luxemburg) (the “Beneficiary”),
and IBI Trust Management (the “Trustee”).

 

WHEREAS,
the Beneficiary holds 3,078,474 shares of Plaza Centers N.V. (a Company incorporated under the laws of the state of Netherlands)
(the “Company”), representing 44.90% of the outstanding share capital of the
Company as of the date hereof; and

 

WHEREAS,
as a controlling shareholder of the Company, the Beneficiary is required to be involved in managing
the Company, which bears significant responsibilities and risks to the Beneficiary; and

 

WHEREAS,
The Beneficiary wishes to cease being considered the controlling1 shareholder in the Company (the “Purpose”)
because the value of the Beneficiary’s holdings in the Company is estimated to be zero, and as such the Beneficiary does
not wish to be exposed to the risks as a controlling shareholder in the Company due to the negligible value of its holdings in
the Company; and 

 

WHEREAS,
In order to achieve the Purpose the Beneficiary want to have 3,078,474 shares of the Company (representing 44.90% of the outstanding
share capital of the Company as of the date hereof) (the “Shares”) and any
other shares of the Company which may be issued with respect to such Shares (the Shares together with such other shares which
may be issued, will hereinafter referred to as the “Trust Assets”), held by
the Trustee in accordance with the terms and conditions of this Agreement; and

 

WHEREAS,
the Trustee has agreed to act as trustee for such purposes, all in accordance with the terms set forth in this Agreement. 

 

NOW
THEREFORE, the parties hereto have agreed as follows:

 

		1.	Appointment
of the Trustee; transfer of the Trust Assets

 

		1.1.	The
                                         Beneficiary hereby irrevocably (subject to the provisions of section 9 below) appoints
                                         the Trustee, starting from the Effective Date, to act as trustee hereunder and to hold
                                         and release the Trust Assets in accordance with the terms and conditions set forth in
                                         this Agreement (the “Trust”).

 

		1.2.	Upon
                                         execution of this Agreement, the Beneficiary, by executing the share transfer deed in
                                         the form attached hereto as Exhibit A, will deposit the Shares with the
                                         Trustee, to be held in Trust for the benefit of the Beneficiary (who will remain the
                                         owner of the Shares) in accordance with the terms and conditions of the Trust.

 

		2.	Rights
                                         of Ownership and Voting; Proxy 

 

		2.1.	The
                                         voting rights in respect of the Trust Assets are vested with the Trustee for all matters
                                         and purposes in the manner that the Beneficiary shall not exercise the voting rights
                                         in connection with the Trust Assets.

 

		2.2.	The
                                         Trustee will not exercise the voting rights in respect of the Trust Assets (i.e. no one
                                         will vote the shares underlying the Trust Assets).

 

		2.3.	The
                                         Beneficiary’s will have the right to receive any and all rights in connection with the
                                         Trust Assets other than the voting rights which are vested with the Trustee as specified
                                         in Sections 2.1 and 2.2 above.

 

		2.4.	Without
                                         derogating from the above, it is made clear that the Trustee will transfer to the Beneficiary
                                         any and all dividends, funds (or assets) upon liquidation and/or other assets (except
                                         for Company’s shares) resulting from the Trust Assets within five (5) business days after
                                         they are received by the Trustee.

 

		2.5.	The
                                         Trustee shall send the Beneficiary a copy of each notice and/or document and/or information
                                         received by him by virtue of being the holder of the Company’s shares, including but
                                         not limited to: proxy statement, proxy card and the like. It should be clarified that
                                         the aforesaid information is required in order to enable the Beneficiary to comply with
                                         its reporting requirements under applicable law.

 

		2.6.	The
                                         Trustee is not allowed to delegate any of his rights and obligations under this Agreement
                                         and its exhibits.

 

 

 

		1	The term “Control” shall have the meaning ascribed to it under the Israeli Securities
Law, 1967.

  

     

     

    

 

		3.	Sale
                                         of Trust Assets

 

		3.1.	The
                                         Beneficiary may instruct the Trustee, from time to time, to sell all or part of the Trust
                                         Assets. In such case the Beneficiary will give the Trustee written instructions with
                                         the exact terms of sale, including: The date of sale, the manner of sale (in a transaction
                                         on the stock exchange or off the stock exchange), the selling price (which may be a certain
                                         price or a minimum price or a market price). The Beneficiary and the Trustee can agree
                                         on any other form of written instructions to the satisfaction of both parties.

  

		3.2.	The
                                         Trustee shall notify the Beneficiary, in writing, immediately after the execution of
                                         any such sale of all or part of the Trust Assets. Such notice will include details about
                                         the amount of Shares sold, the selling price and any other information that the Beneficiary
                                         will require.

 

		3.3.	If
                                         and to the extent that the consideration will be deposited with the Trustee, then no
                                         later than five (5) business days following the consummation of such sale of all or part
                                         of the Trust Assets, the Trustee will transfer the consideration (less bank’s sale fees
                                         and tax, if applicable) to the Beneficiary’s bank account.

 

		3.4.	It
                                         is hereby clarified that in case the Trust Assets will cease to be traded on the London
                                         Stock Exchange Main Market, the sale of the Trust Assets may only be effected through
                                         an off-exchange transaction or any other sale transaction that the Trustee will agree
                                         to in advance.

 

		4.	Certain
                                         Rights of the Trustee 

 

		4.1.	The
                                         Trustee shall have no duties or responsibilities of any kind or nature, whether under
                                         law or under this Agreement, other than those expressly set forth in this Agreement.

 

		4.2.	The
                                         Trustee is authorized to comply with, in the manner determined by the Trustee, and obey
                                         all laws, orders, judgments, decrees and regulations of any governmental authority, court,
                                         tribunal, or arbitrator provided however, that the Trustee will inform the Beneficiary,
                                         as soon as possible, prior to taking any such action .

 

		4.3.	The
                                         Trustee may consult with counsel of its choosing and the opinion of such counsel, in
                                         writing, shall be full, and upon receiving the approval of the Beneficiary, the Trustee
                                         will have complete authorization and protection in respect of any action taken or omitted
                                         by it hereunder in reliance thereon.

 

		4.4.	If
                                         the Trustee is uncertain as to its duties or rights hereunder, the Trustee will address
                                         the Beneficiary for instructions. The Trustee shall not be entitled to any payment, or
                                         expenses, for performing his services hereunder other than the fees as detailed at the
                                         service proposal attached as Exhibit “B”.

 

		4.5.	The
                                         Trustee may rely and shall be protected in acting or refraining from acting, on any Beneficiary’s
                                         resolution, certificate, statement, instrument, opinion, report, notice, request, direction,
                                         consent, order, note or other document believed by it to be genuine and to have been
                                         signed or presented by an authorized person, and, at the Trustee’s discretion,
                                         upon any instruction, consent, statement or request of the Company given orally and is
                                         believed by the Trustee to be given by an authorized officer or other authorized representative
                                         of the Beneficiary.

 

		4.6.	The
                                         Trustee shall not be obligated to recognize nor shall it be required to construe the
                                         contents of any of the documents provided to it. The Trustee may assume the authenticity
                                         of such documents or the signature thereon and shall have no obligation to conduct any
                                         investigation in respect thereof. Without limiting the generality of the foregoing, the
                                         Trustee shall be under no duty whatsoever to make any investigation into the facts or
                                         matters stated in such documents, or to verify the authenticity thereof and may rely
                                         fully on the accuracy of the statements set forth in any such documents.

 

		5.	Termination
                                         of the Trust

 

		5.1.	This
                                         Agreement shall terminate on the earlier of: (i) following the sale of all of the Trust
                                         Assets (Except for a sale as stated in section 9 below); (ii) the date on which actions
                                         have been taken for realization of any of the liens in favor of the holders of the notes
                                         (Series I) of the Company (“Notes”).

 

		5.2.	The
                                         Trustee is entitled to resign from all its duties hereunder at any time it deems proper
                                         by giving the Beneficiary a 60 days prior notice (“Notice”). In such
                                         instance the Trustee shall transfer the Trust Assets to another trustee indicated by
                                         the Beneficiary.

 

		6.	Liability

 

In
connection with the service of the Trustee hereunder and any matter related to the Trust, the Trustee shall not have or incur
any liability for any act or omission of the Trustee except for actions conducted in negligence or willful misconduct.

 

    - 2 -

     

    

 

		7.	Taxes

 

		7.1.	The
                                         Beneficiary shall be responsible for payment of all taxes, duties, compulsory payments,
                                         fees and similar expenses resulting from or relating to the Trust Assets, as required
                                         by law.

 

		7.2.	The
                                         parties agree that the Trustee shall not be required to be stated as the beneficiary
                                         of any of the Trust Assets and that only the Beneficiary shall be deemed to be the sole
                                         beneficiary of such assets.

 

		7.3.	To
                                         the extent required by any applicable law, the Trustee may deduct and withhold from any
                                         payments made by the Trustee under this Agreement any amount that is required by law
                                         to be deducted or withheld.

 

		8.	Confidentiality

 

This
Agreement and all matters concerning the matters covered by this Agreement shall be strictly confidential. The Trustee shall not
disclose This Agreement and all matters concerning the matters covered by this Agreement, to any party and may not use such information
for any purpose other than the purposes set forth herein. However this provision shall not apply to: (i) information which
is publicly known or becomes publicly known without the fault of the Trustee, (ii) information which is required by law to be
disclosed by the Trustee, or (iii) information that is determined by the Trustee and the beneficiary to be required to be disclosed
in order to fulfill this Agreement.

 

		9.	Transfer
                                         and Assignment 

 

It
is agreed that the Beneficiary may resolve to transfer or sale the Trust Assets to a corporation it controls or to a corporation
that controls it (hereinafter: “Transferee”) and in such case the Trust Assets will remain in the possession
of the Trustee and all of the Beneficiary’s rights and liabilities under this Agreement will be assigned to the Transferee. The
Trustee will cooperate with the Beneficiary in order to enable such sale and/or transfer.

 

		10.	Miscellaneous
                                         

 

		10.1.	This
                                         Agreement (and its exhibits), embodies the entire understanding and agreement between
                                         the parties and supersedes all prior agreements and understandings relating to the subject
                                         matter hereof.

 

		10.2.	No
                                         amendment or modification of this Agreement shall be effective or binding unless in writing
                                         and signed by the Beneficiary and the Trustee.

 

		10.3.	The
                                         Beneficiary and the Trustee shall execute and deliver such other documents and shall
                                         perform such acts as is reasonably necessary in order to carry out and give full effect
                                         to the provisions of this Agreement and to the intention of the parties hereunder.

 

		10.4.	All
                                         notices and other communications required or permitted hereunder to be given to a party
                                         to this Agreement shall be in writing and shall be deemed to have been duly given (i)
                                         5 (Five) business days after they are sent by certified mail, return receipt requested,
                                         postage prepaid, addressed to the respective addresses set forth herein, (ii) upon transmission
                                         and the recipient written confirmation of full receipt or (if transmitted and received
                                         on a non-business day) on the first business day following the transmission and the recipient
                                         written confirmation of full receipt, if sent by facsimile or e-mail, or (iii) upon delivery
                                         to the attention of the persons listed herein, if delivered by personal delivery.

 

		10.5.	In
                                         the event that any portion of this Agreement shall be determined to be unlawful, invalid
                                         or unenforceable to any extent, such portion shall be deemed to be amended to conform
                                         with the applicable laws or regulations and the remainder of this Agreement and its application
                                         to persons or circumstances other than to those to which it is determined to be unlawful,
                                         invalid or unenforceable shall not be affected, and each remaining provision of this
                                         Agreement shall continue to have effect.

 

		10.6.	This
                                         Agreement shall be governed by and construed in accordance with the laws of the State
                                         of Israel. The parties irrevocably submit to the sole jurisdiction of the competent courts
                                         in Tel-Aviv - Jaffa, Israel in connection with any legal proceedings relating to this
                                         Agreement and any matter arising with respect thereto.

 

[Signature
page follows]

 

    - 3 -

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.

 

	THE BENEFICIARY:	 
		 
	 	 
	Elbit Ultrasound BV	 
	 	 
	THE TRUSTEE:	 
	 	 
	 	 
	IBI Trust Management	 

 

[Signature Page
for Escrow Agreement]

 

    

     

    

 

AMENDMENT
No. 1 TO ESCROW AGREEMENT

 

This
Amendment to the Trust Agreement (the “Amendment”) is entered into this 18 day of December, 2018, by and among
Elbit Ultrasound BV (a Company incorporated under the laws of the state of Luxemburg) (the “Beneficiary”),
and IBI Trust Management (the “Trustee”).

 

WHEREAS,
the Beneficiary and the Trustee are parties to a certain Trust Agreement, dated December 5, 2018 (the: “Trust Agreement”);
and

 

WHEREAS,
the Beneficiary and the Trustee have agreed to amend the Trust Agreement, as set forth below;

 

THEREFORE,
the parties hereto agree as follows:

 

		1.	General

 

		1.1.	The
preamble to this Amendment constitute an integral part hereof.

 

		1.2.	The
                                         headings in this Amendment are for the purpose of convenience only and shall not be used
                                         for the purposes of interpretation.

 

		1.3.	All
                                         capitalized terms used in this Amendment that are not defined in this Amendment but are
                                         defined in the Trust Agreement, shall have the definitions given to them in the Trust
                                         Agreement.

 

		1.4.	Section
                                         1 of the Trust Agreement will be deleted and replaced with Section 1 below:

 

		2.	Appointment
of the Trustee; transfer of the Trust Assets

 

		2.1.	The
                                         Beneficiary hereby irrevocably (subject to the provisions of section 9 below) appoints
                                         the Trustee, starting from December 18, 2018 (the “Effective Date”),
                                         to act as trustee hereunder and to hold and release the Trust Assets in accordance with
                                         the terms and conditions set forth in this Agreement (the “Trust”).

 

		2.2.	Upon
                                         execution of this Agreement, the Beneficiary, will execute the share transfer deed in
                                         the form attached hereto as Exhibit A, for the transfer of the Shares to
                                         the Trustee, to be held in Trust, Starting from the Effective Date, for the benefit of
                                         the Beneficiary (who will remain the owner of the Shares) in accordance with the terms
                                         and conditions of the Trust.

 

		2.3.	Section
                                         2.1 of the Trust Agreement will be deleted and replaced with Section 2.1 below:

 

		2.4.	Starting
                                         from the Effective Date, the voting rights in respect of the Trust Assets are vested
                                         with the Trustee for all matters and purposes in the manner that the Beneficiary shall
                                         not exercise the voting rights in connection with the Trust Assets.

 

		2.5.	Except
                                         as set forth herein, this Amendment shall not affect any other provisions in the Trust
                                         Agreement, which shall remain in full force and effect. In the event of any conflict
                                         or contradiction arising between the provisions of this Amendment and the Trust Agreement,
                                         the provisions of this Amendment shall prevail.

 

[Signature
page follows]

 

    

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Agreement to be duly executed on the date first above written.

 

	THE BENEFICIARY:	 
	 	 
	 	 
	Elbit Ultrasound BV	 
	 	 
	THE TRUSTEE:	 
	 	 
	 	 
	IBI Trust Management	 

 

 

 

 

[Signature
Page for Escrow Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]